Eli Lilly and Company (LLY)
| Market Cap | 682.35B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 61.85 |
| Forward PE | 30.21 |
| Dividend | $6.00 (0.79%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 4,270,876 |
| Open | 774.00 |
| Previous Close | 762.95 |
| Day's Range | 758.41 - 778.10 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 1,015.65 (+33.62%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,015.65, which is an increase of 33.62% from the latest price.
News
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the valu...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook a...
What other health conditions are weight-loss drugs being tested for?
Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival medicines Ozempic and Wegovy are being studied to see whether they can improve health i...
LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with high unmet need.
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when tested in patients with a type of blood cancer.
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Thousands of Americans are being forced to switch from Zepbound to Wegovy as a result of new coverage restrictions by CVS Caremark. ‘I just wish they would trust my doctor.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
The Big 3: OKTA, LLY, ADSK
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technica...
EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain patients with early Alzheimer's disease, reversing an initial decision from f...
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Bosto...
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today t...
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be e...
Chewy, Eaton and 2 Other Stocks Set to Gain After Earnings, Says Morgan Stanley
Morgan Stanley strategists highlighted companies that look likely to report strong numbers, including Chewy, Eaton, Nvidia, and Eli Lilly.
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that...
This Weight-Loss Stock Sank After Earnings. It's Still a Risk for Eli Lilly, Novo Nordisk.
Viking Therapeutics is expected to disclose data on its oral weight-loss drug VK2735.
Lilly and Verve announce expiration of Verve tender offer
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outst...
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
BRISBANE, Calif.--(BUSINESS WIRE)--Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
15 stocks of companies set to grow sales twice as fast as the S&P 500 — analysts love them
Growth stocks can be expensive, but if you are trying to be aggressive with a portion of your investment portfolio, you often have to pay a premium for the privilege.
Eli Lilly: Competition Melts Away
Eli Lilly's Tirzepatide has won over Novo's Semaglutide in the GLP-1 race in both glucose control and weight loss, driving market share gains. Retatrutide and Orforglipron signal a similar Next-Gen do...
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients a...
Calls of the Day: Eli Lilly and Materion
The Investment Committee debate the latest Calls of the Day.
Orr: PLTR & NVDA are Overvalued, GOOGL & LLY Great Upcoming Picks
Steven E. Orr finds Palantir (PLTR) overvalued right now and is looking for it to pull back to $100/share. He feels the same about Nvidia (NVDA), citing market FOMO.
Eli Lilly Comes Out As ADA Winner
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Fav...